David Terreson
Interventional Cardiology · Austin, TXNPI 1417932120
Payments from drug & device makers
Across 428 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$1K
- Cvrx, Inc.$766
- Novo Nordisk$501
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$495
- Johnson & Johnson$440
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,278100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 69 | $1,167 |
| Amgen | 87 | $1,031 |
| Cvrx, Inc. | 19 | $766 |
| Novo Nordisk | 14 | $501 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $495 |
| Johnson & Johnson | 29 | $440 |
| Boehringer Ingelheim | 23 | $401 |
| Pfizer | 23 | $392 |
| AstraZeneca | 14 | $360 |
| Amarin Pharma, Inc. | 12 | $322 |
| Sanofi-aventis U.S. LLC | 5 | $308 |
| Abbott | 5 | $295 |
| Esperion Therapeutics, Inc. | 6 | $219 |
| Actelion Pharmaceuticals US, Inc. | 19 | $198 |
| Bayer | 10 | $198 |
| Impulse Dynamics (USA) Inc. | 11 | $181 |
| E.r. Squibb & Sons, L.L.C. | 9 | $168 |
| Akcea Therapeutics, Inc. | 6 | $164 |
| Regeneron Healthcare Solutions, Inc. | 10 | $151 |
| Abiomed | 4 | $84 |
| Althera Pharmaceuticals LLC | 6 | $80 |
| Arbor Pharmaceuticals, Inc. | 5 | $74 |
| Boston Scientific | 2 | $44 |
| Itamar Medical Inc | 1 | $37 |
| Merck | 2 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $25 |
| Acist Medical Systems, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Vital Connect, Inc | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Regeneron | 1 | $16 |
| Preventice Services, LLC | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
| Getinge USA Sales, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$428
- Ozempic$249
- MitraClip$174
- FARXIGA$125
- NEXLIZET$125
- NEXLETOL$125
- DISEASE STATE$123
- PRALUENT$122
- Vascepa$115
How this compares
$8,304 in reported general payments places this provider in the 40th percentile of 686 interventional cardiology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 43 | $42,722 |
| EntrestoSacubitril/Valsartan | 18 | $22,642 |
| Repatha SureclickEvolocumab | 18 | $12,648 |
| Repatha PushtronexEvolocumab | 13 | $7,414 |
| Flecainide Acetate | 28 | $1,073 |
| Nebivolol Hcl | 17 | $772 |
| Metoprolol Succinate | 50 | $762 |
| Ezetimibe | 35 | $634 |
| Rosuvastatin Calcium | 52 | $626 |
| Valsartan | 20 | $554 |
| Atorvastatin Calcium | 37 | $451 |
| Carvedilol | 32 | $335 |
| Amlodipine Besylate | 51 | $324 |
| Losartan Potassium | 31 | $305 |
| Pravastatin Sodium | 23 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $440 | $42,72243 claims |
| NovartisEntresto | $1,167 | $22,64218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Austin
- Mark PirwitzAustin$2.4M
- Francis ZidarAustin$1.8M
- Juhana KarhaAustin$842K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.